-
公开(公告)号：US20230338356A1
公开(公告)日：2023-10-26
申请号：US18184657
申请日：2023-03-16
发明人： Robert MOORE , Isana ENDO , Carl FIRTH , Stephen DOYLE
IPC分类号： A61K31/455 , A61P37/06 , A61P17/00
CPC分类号： A61K31/455 , A61P37/06 , A61P17/00
摘要： A method of treating an autoimmune skin disease in a patient comprising administering a therapeutically effective amount of a DHODH inhibitor or a pharmaceutically acceptable salt thereof. Also provided are formulations or compositions suitable for treating autoimmune skin diseases.
-
公开(公告)号：US20230091430A1
公开(公告)日：2023-03-23
申请号：US17929874
申请日：2022-09-06
发明人： Karen VEVERKA , Alison WARD
摘要： An antibody, antigen binding fragment thereof and compositions comprising the same, which is an inhibitor of signalling through IL-13Rα1, by binding the said receptor, for use in the treatment of allergic disease, such as atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) in a highly allergic patient where the baseline IgE levels have been established and are at a level of at least 10,000 KU/L+/−2,000.
-
公开(公告)号：US20210277131A1
公开(公告)日：2021-09-09
申请号：US17272243
申请日：2020-03-26
发明人： Alison WARD
摘要： The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600 mg to 900 mg at least once each month, in particular less than twice a month.
-
公开(公告)号：US10682353B2
公开(公告)日：2020-06-16
申请号：US15757189
申请日：2016-09-05
发明人： Bertil Lindmark , Lisa Ooi
IPC分类号： A61K31/517 , C07D239/94 , A61K31/51 , A61P35/00 , A61K9/00 , A61K31/7068 , A61K33/24 , A61K31/282 , A61K31/513
摘要： The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
-
公开(公告)号：US20190151326A1
公开(公告)日：2019-05-23
申请号：US16252452
申请日：2019-01-18
发明人： Bertil Lindmark , Ann Gee Lisa Ooi
IPC分类号： A61K31/5377 , A61P35/02 , A61K31/517 , A61K31/4545 , A61K31/075 , A61K31/502 , A61K31/201 , A61K31/4745
摘要： A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
-
公开(公告)号：US20210379070A1
公开(公告)日：2021-12-09
申请号：US17283724
申请日：2019-10-09
发明人： Robert MOORE
IPC分类号： A61K31/517 , C07D417/14 , A61K33/243 , A61K31/282 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/519 , A61K31/4745
摘要： The present disclosure relates to a pharmaceutically acceptable salt of compounds (I), i.e. varlitinib, a method of producing the salt, a purer form of the free base obtainable from the salt, and a pharmaceutical composition comprising any one of the same. Also provided is a salt, free base or composition thereof for use in treatment, in particular the treatment of cancer, including as part of a combination therapy, for example in combination with a chemotherapeutic agent. The disclosure also extends to compositions comprising the same and use of any one of the same in treatment, in particular treatment of cancer.
-
公开(公告)号：US20200165347A1
公开(公告)日：2020-05-28
申请号：US16625902
申请日：2018-06-29
发明人： Bertil Lindmark , Ann Gee Lisa Ooi
摘要： The present disclosure provides a method of treating cutaneous T cell lymphoma (CTCL), in particular mycosis fungoides and/or Sézary syndrome, comprising administering a therapeutically effective amount of an antagonist antibody or binding fragment thereof specific to the IL-13 receptor to a patient in need thereof.
-
公开(公告)号：US20200009144A1
公开(公告)日：2020-01-09
申请号：US16508444
申请日：2019-07-11
发明人： Bertil Lindmark , Lisa Ooi
IPC分类号： A61K31/517 , C07D239/94 , A61K31/51 , A61P35/00 , A61K9/00 , A61K31/7068 , A61K33/24
摘要： In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; a) a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and b) a chemotherapeutic agent or a combination of chemotherapeutic agents
-
公开(公告)号：US20190134034A1
公开(公告)日：2019-05-09
申请号：US16094199
申请日：2017-04-21
发明人： Lisa Ooi , Bertil Lindmark
IPC分类号： A61K31/513 , A61P35/00 , A61K31/455 , A61K31/4745 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/704 , A61K31/7068 , A61K33/24
摘要： A method of treating liver cancer, such as hepatocellular carcinoma, by administering a compound of formula (I), such as Varlitinib, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (I) for use in the treatment of liver cancer and use of a compound of formula (I) in the manufacture of a medicament for the treatment of liver cancer.
-
公开(公告)号：US20180353510A1
公开(公告)日：2018-12-13
申请号：US15757166
申请日：2016-09-05
发明人： Bertil Lindmark , Mark Thomas McHale , Lisa Ooi
IPC分类号： A61K31/517 , A61K9/00 , A61P35/00
CPC分类号： A61K31/517 , A61K9/0053 , A61K31/282 , A61K31/51 , A61K31/513 , A61K31/7068 , A61K33/24 , A61K2300/00 , A61P35/00
摘要： The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.019 秒)
